Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field

References

• Neofytos D, Lu K, Hatfield-Seung A, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013;75(2):144–149.
   PubMed Web of Science ®Google Scholar
• Corzo-Leon DE, Satlin MJ, Soave R, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325–336.
   PubMed Web of Science ®Google Scholar
• Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115–121.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55(5):1953–1960.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Sadique Z, Harris R, et al. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. J Antimicrob Chemother. 2015;70(4):1175–1181.
   PubMed Web of Science ®Google Scholar
• Even C, Bastuji-Garin S, Hicheri Y, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica. 2011;96(2):337–341.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25(1):107–115.
   PubMed Web of Science ®Google Scholar
• Hori A, Kami M, Kim SW, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant. 2004;10(1):65–72.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bregni M, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant. 2013;48(9):1161–1167.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(6):872–880.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102(3):827–833.
   PubMed Web of Science ®Google Scholar
• Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5–i14.
   PubMed Web of Science ®Google Scholar
• Montagna MT, Lovero G, Coretti C, et al. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection. 2014;42(1):141–151.
   PubMed Web of Science ®Google Scholar
• Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008;68(14):1941–1962.
   PubMed Web of Science ®Google Scholar
• Tang JL, Kung HC, Lei WC, et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS One. 2015;10(6):e0128410.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97(3):459–463.
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96(6):748–757.
   PubMed Web of Science ®Google Scholar
• Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiology Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2013;19(8):745–751.
   PubMed Web of Science ®Google Scholar
• Harrison N, Mitterbauer M, Tobudic S, et al. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study. BMC Infect Dis. 2015;15:584.
   PubMed Web of Science ®Google Scholar
• Brissot E, Cahu X, Guillaume T, et al. Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Ann Hematol. 2015;94(4):663–669.
   PubMed Web of Science ®Google Scholar
• Omer AK, Ziakas PD, Anagnostou T, et al. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013;19(8):1190–1196.
   PubMed Web of Science ®Google Scholar
• Stanzani M, Lewis RE, Fiacchini M, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One. 2013;8(9):e75531.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant. 2004;10(7):494–503.
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, Van Burik JA, et al. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175(6):1459–1466.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–1050.
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116(2):475–482.
   PubMed Web of Science ®Google Scholar
• Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8(9):512–520.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009;44(6):361–370.
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23–S34.
   PubMed Web of Science ®Google Scholar
• Garnica M, Da Cunha MO, Portugal R, et al. Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients. Clin Infect Dis. 2015;60(6):875–880.
   PubMed Web of Science ®Google Scholar
• Caira M, Candoni A, Verga L, et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015;100(2):284–292.
   PubMed Web of Science ®Google Scholar
• Bodey GP. Infectious complications of acute leukemia. Med Times. 1966;94(9):1076–1085.
   PubMedGoogle Scholar
• Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009;27(23):3849–3854.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100(3):345–351.
   PubMed Web of Science ®Google Scholar
• Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110(2):273–284.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Strenger V, Buzina W, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. 2012;67(8):2029–2033.
   PubMed Web of Science ®Google Scholar
• Matsumura-Kimoto Y, Inamoto Y, Tajima K, et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(6):1102–1107.
   PubMed Web of Science ®Google Scholar
• Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol. 2001;66(4):257–262.
   PubMed Web of Science ®Google Scholar
• Arnow PM, Andersen RL, Mainous PD, et al. Pumonary aspergillosis during hospital renovation. Am Rev Respir Dis. 1978;118(1):49–53.
   PubMed Web of Science ®Google Scholar
• Krasinski K, Holzman RS, Hanna B, et al. Nosocomial fungal infection during hospital renovation. Infection Control IC. 1985;6(7):278–282.
   PubMedGoogle Scholar
• Lentino JR, Rosenkranz MA, Michaels JA, et al. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol. 1982;116(3):430–437.
   PubMed Web of Science ®Google Scholar
• Sarubbi FA Jr., Kopf HB, Wilson MB, et al. Increased recovery of aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis. 1982;125(1):33–38.
   PubMed Web of Science ®Google Scholar
• Streifel AJ, Lauer JL, Vesley D, et al. Aspergillus fumigatus and other thermotolerant fungi generated by hospital building demolition. Appl Environ Microbiol. 1983;46(2):375–378.
   PubMed Web of Science ®Google Scholar
• Weems JJ Jr., Davis BJ, Tablan OC, et al. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infection Control IC. 1987;8(2):71–75.
   PubMedGoogle Scholar
• Cornet M, Levy V, Fleury L, et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol. 1999;20(7):508–513.
   PubMed Web of Science ®Google Scholar
• Withington S, Chambers ST, Beard ME, et al. Invasive aspergillosis in severely neutropenic patients over 18 years: impact of intranasal amphotericin B and HEPA filtration. J Hosp Infect. 1998;38(1):11–18.
   PubMedGoogle Scholar
• Abdul SZH, Karlin RB, Ling ML, et al. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am J Infect Control. 2010;38(4):e1–e7.
   PubMed Web of Science ®Google Scholar
• Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987;83(4):709–718.
   PubMed Web of Science ®Google Scholar
• Benet T, Nicolle MC, Thiebaut A, et al. Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis. 2007;45(6):682–686.
   PubMed Web of Science ®Google Scholar
• Teng JC, Slavin MA, Teh BW, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462–e466.
   PubMed Web of Science ®Google Scholar
• Doan TN, Kirkpatrick CM, Walker P, et al. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. J Antimicrob Chemother. 2016;71(2):497–505.
   PubMed Web of Science ®Google Scholar
• Henden A, Morris K, Truloff N, et al. Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis. Leuk Lymphoma. 2013;54(6):1329–1331.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Leguay T, Maertens J A double-blind, multicentre, randomised, placebo-controlled study to assess the efficacy, safety and tolerability of prophylactic liposomal amphotericin B (AmBisome®) for the prevention of invasive fungal infections in subjects receiving remission-induction chemotherapy for acute lymphoblastic leukaemia (AmBiGuard trial) [abstract]. 56th ASH Annual Meeting and Exposition San Francisco, CA. Dec 6-9, 2014. Abstract 3646.).
   Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet. Haematol. 2016;3(3):e119–e127.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Royo-Cebrecos C, Peghin M, et al. Environmental variables associated with an increased risk of invasive aspergillosis. Clin Microbiology Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2014;20(11):O939–O945.
   PubMed Web of Science ®Google Scholar
• Ozyilmaz E, Aydogdu M, Sucak G, et al. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010;45(10):1528–1533.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303–1306.
   PubMed Web of Science ®Google Scholar
• O’Brien SN, Blijlevens NM, Mahfouz TH, et al. Infections in patients with hematological cancer: recent developments. Hematology /the Education Program of the American Society of Hematology. American Society of Hematology, Washington, DC. Education Program; 2003. p. 438–472.
   Google Scholar
• Wojtowicz A, Bochud PY. Host genetics of invasive aspergillus and Candida infections. Semin Immunopathol. 2015;37(2):173–186.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766–1777.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Carotti A, et al. Polymorphisms in toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. Exp Hematol. 2009;37(9):1022–1029.
   PubMed Web of Science ®Google Scholar
• Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood. 2010;116(24):5394–5402.
   PubMed Web of Science ®Google Scholar
• Chai LY, De Boer MG, Van Der Velden WJ, et al. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis. 2011;203(5):736–743.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Desai SR, Berry L, et al. A comprehensive diagnostic approach using galactomannan, targeted beta-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. Br J Haematol. 2015;168(2):219–229.
   PubMed Web of Science ®Google Scholar
• Bow EJ, Loewen R, Cheang MS, et al. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21(2):361–369.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Reichert D, et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother. 2008;61(4):939–946.
   PubMed Web of Science ®Google Scholar
• Heng SC, Slavin MA, Al-Badriyeh D, et al. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. J Antimicrob Chemother. 2013;68(7):1669–1678.
   PubMed Web of Science ®Google Scholar
• Lewis G, Hall P, Eisa N, et al. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. Acta Haematologica. 2010;124(4):206–213.
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132(1):3–12.
   PubMed Web of Science ®Google Scholar
• Brenier-Pinchart MP, Lebeau B, Quesada JL, et al. Influence of internal and outdoor factors on filamentous fungal flora in hematology wards. Am J Infect Control. 2009;37(8):631–637.
   PubMed Web of Science ®Google Scholar
• Panackal AA, Li H, Kontoyiannis DP, et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis. 2010;50(12):1588–1597.
   PubMed Web of Science ®Google Scholar
• Blum G, Eschertzhuber S, Auberger J, et al. Airborne fungus exposure prior to hospitalisation as risk factor for mould infections in immunocompromised patients. Mycoses. 2012;55(3):237–243.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272:23–30.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Kerremans JJ, Voss A, et al. Fungal contamination of tobacco and marijuana. Jama. 2000;284(22):2875.
   PubMed Web of Science ®Google Scholar
• Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–1297.
   PubMed Web of Science ®Google Scholar
• Alves De Medeiros AK, Lodewick E, Bogaert DJ, et al. Chronic and invasive fungal infections in a family with CARD9 deficiency. J Clin Immunol. 2016;36(3):204–209.
   PubMed Web of Science ®Google Scholar
• Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370(5):421–432.
   PubMed Web of Science ®Google Scholar
• Shelburne SA, Ajami NJ, Chibucos MC, et al. Implementation of a pan-genomic approach to investigate holobiont-infecting microbe interaction: a case report of a leukemic patient with invasive mucormycosis. PLoS One. 2015;10(11):e0139851.
   PubMed Web of Science ®Google Scholar
• Oever JT, Netea MG. The bacteriome-mycobiome interaction and antifungal host defense. Eur J Immunol. 2014;44(11):3182–3191.
   PubMed Web of Science ®Google Scholar
• Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax. 1991;46(1):15–20.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Wang L, Hu J, Sun Y, et al. Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy: a multicenter, prospective, observational study in China. Medicine. 2016;95(4):e2560.
   PubMed Web of Science ®Google Scholar
• Pomares H, Arnan M, Sanchez-Ortega I, et al. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses. 2016;59(8):516–519.
   PubMed Web of Science ®Google Scholar
• Chau MM, Kong DC, Van Hal SJ, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014;44(12b):1364–1388.
   PubMed Web of Science ®Google Scholar
• CDC and the Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia. Centers for Diseases Control, Atlanta, Georgia. 2003.
   Google Scholar
• Chang CC, Ananda-Rajah M, Belcastro A, et al. Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Intern Med J. 2014;44(12b):1389–1397.
   PubMed Web of Science ®Google Scholar
• Yonemori K, Takezako N, Nishimura K, et al. Fungal infection in neutropenic patients in a hospital during construction. Jpn J Infect Dis. 2002;55(4):126–127.
   PubMed Web of Science ®Google Scholar
• Douglas AP, Thursky KA, Slavin MA. Invasive fungal infections in ALL: a new ‘growth’ area. Leuk Lymphoma. 2016;57(9):1985–1987.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55(4):290–297.
   PubMed Web of Science ®Google Scholar
• Nicolato A, Nouer SA, Garnica M, et al. Invasive fungal diseases in patients with acute lymphoid leukemia. Leuk Lymphoma. 2016;57(9):2084–2089.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–1075.
   PubMed Web of Science ®Google Scholar
• Teh BW, Teng JC, Urbancic K, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28–e31.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Ascioglu S, Moreau P, et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European organization for research and treatment of cancer/invasive fungal infections cooperative group and the intergroupe Francais du myelome. Clin Infect Dis. 2000;30(1):41–46.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• FDA alerts healthcare professionals about clinical trials with Zydelig® (idelalisib) in combination with other cancer medicines. FDA drug safety and availability. Washington, DC. Available from: www.fda.gov/Drugs/DrugSafety/ucm490618.htm [ cited 2016 Jul 21].
   Google Scholar
• Sun Y, Meng F, Han M, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant. 2015;21(6):1117–1126.
   PubMed Web of Science ®Google Scholar
• Parody R, Martino R, Rovira M, et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12(7):734–748.
   PubMed Web of Science ®Google Scholar
• Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant. 2007;13(7):771–777.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol. 2004;73(3):174–178.
   PubMed Web of Science ®Google Scholar
• Fuji S, Kapp M, Einsele H. Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2013;4:276.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721–1726.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Moreton P, et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 2004;103(6):2027–2031.
   PubMed Web of Science ®Google Scholar
• Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma. 2004;4(4):220–227.
   PubMedGoogle Scholar
• Gibbs SD, Westerman DA, McCormack C, et al. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol. 2005;130(1):87–91.
   PubMed Web of Science ®Google Scholar
• Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol. 2009;26(3):175–183.
   PubMed Web of Science ®Google Scholar
• Gil L, Kozlowska-Skrzypczak M, Mol A, et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant. 2009;43(2):121–126.
   PubMed Web of Science ®Google Scholar
• Tse E, Leung RY, Kwong YL. Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Ann Hematol. 2015;94(1):165–167.
   PubMed Web of Science ®Google Scholar
• Van Oers MH. CD20 antibodies: type II to tango? Blood. 2012;119(22):5061–5063.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181–194.
   PubMed Web of Science ®Google Scholar
• Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004;34(6):505–509.
   PubMed Web of Science ®Google Scholar
• Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307–312.
   PubMed Web of Science ®Google Scholar
• De Pauw BEDJ. Prophylaxis and aspergillosis- has the principle been proven? N Eng J Med. 2007;356:409–411.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther. 2014;36(2):292–306.e291.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466–1471.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Michallet M, Sobh M, Morisset S, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol. 2011;49(7):681–687.
   PubMed Web of Science ®Google Scholar
• Egerer G, Geist MJ. Posaconazole prophylaxis in patients with acute myelogenous leukaemia–results from an observational study. Mycoses. 2011;54(Suppl 1):7–11.
   PubMed Web of Science ®Google Scholar
• Shen Y, Huang XJ, Wang JX, et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther. 2013;51(9):738–745.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis. 2012;55(11):1515–1521.
   PubMed Web of Science ®Google Scholar
• Biehl LM, Vehreschild JJ, Liss B, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71:2634–2641.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19(1):19–26.
   PubMed Web of Science ®Google Scholar
• Gomes MZ, Mulanovich VE, Jiang Y, et al. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother. 2014;58(2):865–873.
   PubMed Web of Science ®Google Scholar
• Shi JM, Pei XY, Luo Y, et al. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B. 2015;16(9):796–804.
   PubMed Web of Science ®Google Scholar
• Morrissey COCS, Sorrell TC, Milliken S, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13:519–528.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–5118.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59(12):1696–1702.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Bartoni K, Territo MC, et al. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(4):507–515.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ortega I, Patino B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2011;46(5):733–739.
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–327.
   PubMed Web of Science ®Google Scholar
• Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416.
   PubMed Web of Science ®Google Scholar
• Hiramatsu Y, Maeda Y, Fujii N, et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol. 2008;88(5):588–595.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen H, Han M, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012;18(10):1509–1516.
   PubMed Web of Science ®Google Scholar
• Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12):1644–1650.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Barosi G, Piciocchi A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(8):1080–1088.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46(5):709–718.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2016;14(7):882–913.
   PubMed Web of Science ®Google Scholar
• Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26(2):220–252.
   PubMedGoogle Scholar
• Tacke D, Buchheidt D, Karthaus M, et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the infectious diseases working party of the German society for haematology and oncology. Ann Hematol. 2014;93(9):1449–1456.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study–sorveglianza epidemiologica infezioni fungine nelle emopatie maligne. Clin Infect Dis. 2007;45(9):1161–1170.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–1552.
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–211.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis. 2012;25(6):605–611.
   PubMed Web of Science ®Google Scholar
• Neubauer WC, Engelhardt M, Konig A, et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother. 2010;54(9):4029–4032.
   PubMedGoogle Scholar
• Hope WW, Walsh TJ, Goodwin J, et al. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. J Antimicrob Chemother. 2016;71:2234–2240.
   PubMed Web of Science ®Google Scholar
• Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762–1769.
   PubMed Web of Science ®Google Scholar
• Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a lightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;125(2):196–202.
   PubMed Web of Science ®Google Scholar
• Heng SC, Morrissey O, Chen SC, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol. 2015;41(1):124–134.
   PubMed Web of Science ®Google Scholar